Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

The two biggest weight-loss drugmakers have lost $252bn in value this year, as investor enthusiasm for obesity treatments wanes and Donald Trump’s tariff and price-cut threats weigh on the ...